Health Tech

Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025

Hims & Hers Health, Inc. (NYSE: HIMS) is back in the market spotlight. As of early December 5, 2025, the telehealth company’s stock is trading around $40 per share, up sharply from recent lows but still far below its 52‑week

5 December 2025

Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health, Inc. (NYSE: HIMS) is in the spotlight today after officially rolling out its new “Labs” diagnostic platform in partnership with Quest Diagnostics, even as the stock trades sharply lower and Wall Street sentiment turns more cautious.

14 November 2025

Business News · Financial Updates · Health Tech · Investments · NYSE:HIMS · Stock Market

Oracle Stock Surges on $300B AI Cloud Deal – Is a Trillion-Dollar Valuation Next?

Oracle Stock Today (Nov 7, 2025): ORCL Slips on Oracle‑Linked Cyber Breach Headlines as New Health‑AI Partnership Lands

Updated: November 7, 2025 Oracle (NYSE: ORCL) shares were lower in midday trading on Friday after fresh headlines tied a high‑profile cyber breach to Oracle software, partially offsetting a same‑day announcement of a new oncology data and AI collaboration. As

7 November 2025

Artificial Intelligence · Business News · Cybersecurity · NYSE:ORCL · Oracle · Stock Market

Global Wearable Health Tech News – June and July 2025

Biobeat’s cuffless vital-sign patch received FDA clearance and CE marking for hospital-grade remote monitoring, enabling cuffless measurement of blood pressure, heart rate, SpO2, and respiratory rate via PPG and AI. On June 19, PharmaSens and SiBionics announced niia™ signature, an

7 July 2025

Digital Health · Health Tech · Industry News · NASDAQ:AAPL · NASDAQ:DXCM · NYSE:ABT · Technology · Wearables

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began

27 June 2025

2025 Trends · Biotechnology · Forecast · Health Tech · Medical Innovation · NASDAQ:ABEO · NASDAQ:ITCI · NASDAQ:PRME · NASDAQ:RARE · NASDAQ:RGLS · NASDAQ:SWTX · NASDAQ:VRTX · NASDAQ:WVE · NYSE:AZN · NYSE:CTLT · NYSE:JNJ · NYSE:NVO · NYSE:NVS

Trends 2025: Consumer Electronics & Wearables – AI, AR, Health Tech and More (Updated: June 27th, 2025)

Global consumer tech sales are projected to reach $1.29 trillion in 2025, about 2% growth over 2024. Apple leads wearables with roughly a 20–25% global market share in recent quarters, driven by its Watch and AirPods lines. Wearable shipments grew

27 June 2025

2025 Trends · Artificial Intelligence · Consumer Electronics · Health Tech · Wearables